Sanofi's Nirsevimab Study to Assess RSV Immunisation Rates in Queensland Infants
A study sponsored by Sanofi aims to determine nirsevimab immunisation rates among infants in Queensland during the RSV season.
Asset / Drug
Drug and asset intelligence for Nirsevimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.